- Home
- TSHA vs LXFR Comparison
TSHA vs LXFR Comparison
Compare TSHA & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- LXFR
- Stock Information
- Founded
- TSHA 2019
- LXFR 1898
- Country
- TSHA United States
- LXFR United States
- Employees
- TSHA N/A
- LXFR N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- LXFR Major Chemicals
- Sector
- TSHA Health Care
- LXFR Industrials
- Exchange
- TSHA Nasdaq
- LXFR Nasdaq
- Market Cap
- TSHA 334.1M
- LXFR 380.9M
- IPO Year
- TSHA 2020
- LXFR 2012
- Fundamental
- Price
- TSHA $1.72
- LXFR $12.03
- Analyst Decision
- TSHA Strong Buy
- LXFR
- Analyst Count
- TSHA 8
- LXFR 0
- Target Price
- TSHA $6.63
- LXFR N/A
- AVG Volume (30 Days)
- TSHA 1.5M
- LXFR 169.0K
- Earning Date
- TSHA 02-26-2025
- LXFR 04-29-2025
- Dividend Yield
- TSHA N/A
- LXFR 4.29%
- EPS Growth
- TSHA N/A
- LXFR N/A
- EPS
- TSHA N/A
- LXFR 0.68
- Revenue
- TSHA $8,333,000.00
- LXFR $391,900,000.00
- Revenue This Year
- TSHA N/A
- LXFR $2.26
- Revenue Next Year
- TSHA N/A
- LXFR $5.85
- P/E Ratio
- TSHA N/A
- LXFR $17.84
- Revenue Growth
- TSHA N/A
- LXFR N/A
- 52 Week Low
- TSHA $1.19
- LXFR $9.26
- 52 Week High
- TSHA $4.32
- LXFR $15.64
- Technical
- Relative Strength Index (RSI)
- TSHA 54.31
- LXFR 35.81
- Support Level
- TSHA $1.66
- LXFR $11.86
- Resistance Level
- TSHA $1.77
- LXFR $12.62
- Average True Range (ATR)
- TSHA 0.11
- LXFR 0.64
- MACD
- TSHA 0.01
- LXFR -0.07
- Stochastic Oscillator
- TSHA 47.62
- LXFR 25.16
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.